Literature DB >> 3892880

Experimental and clinical trials of long acting oxytetracycline in the treatment of canine ehrlichiosis.

A B Ogunkoya, J B Adeyanju, R Abduhllahi.   

Abstract

Four splenectomized dogs were experimentally infected with Ehrlichia canis and treated at the point of illness with long acting (LA) Oxytetracycline at different dosages. Terramycin LA, when given at a dose of 20 mg/kg body weight (deep intramuscularly) twice, at a four-day interval, was found to have effectively controlled the disease and has replaced the usual 7-14 successive days' treatment regimen when other groups of tetracycline drugs are used. Predef 2X at the rate of 2 mg given intramuscularly concurrently eliminated the local inflammatory reaction caused by the injection of Terramycin LA. Twenty-four out of the 26 naturally infected dogs which were treated in a similar way were completely cured; one died before it could receive the full treatment, and another received a second medication five weeks after the first treatment, showing recurrent epistaxis; blood samples taken from this dog were negative for E. canis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3892880     DOI: 10.1080/01652176.1985.9693974

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  3 in total

1.  A Case of Intranasal Hemangioma and Concurrent Tetracycline-induced Ulcerative Gastritis in Dogs.

Authors:  H S Banga; S Deshmukh; R S Brar; P D Gadhave; S G Chavhan; H S Sandhu
Journal:  Toxicol Int       Date:  2010-01

2.  The pharmacokinetics of a long-acting oxytetracycline formulation in healthy dogs and in dogs infected with Ehrlichia canis.

Authors:  G M Kikuvi; E S Mitema; I B Buoro
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

3.  Tick acquisition of Ehrlichia canis from dogs treated with doxycycline hyclate.

Authors:  John J Schaefer; Glen R Needham; William G Bremer; Yasuko Rikihisa; S A Ewing; R W Stich
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.